| Title: |
Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. |
| Authors: |
Kahlert, Christian R, Strahm, Carol, Güsewell, Sabine, Cusini, Alexia, Brucher, Angela, Goppel, Stephan, Möller, Elisabeth, Möller, J Carsten, Ortner, Manuela, Ruetti, Markus, Stocker, Reto, Vuichard-Gysin, Danielle, Besold, Ulrike, McGeer, Allison, Risch, Lorenz, Friedl, Andrée, Schlegel, Matthias, Vernazza, Pietro, Kuster, Stefan P, Kohler, Philipp |
| Source: |
Clinical Infectious Diseases; 7/15/2023, Vol. 77 Issue 2, p194-202, 9p |
| Subject Terms: |
RESEARCH, COVID-19, CONFIDENCE intervals, POST-acute COVID-19 syndrome, SICK people, COVID-19 vaccines, CROSS-sectional method, SELF-evaluation, MEDICAL personnel, REGRESSION analysis, VACCINE effectiveness, RISK assessment, RESEARCH funding, DESCRIPTIVE statistics, VACCINATION status, ODDS ratio, LONGITUDINAL method, DISEASE risk factors, SYMPTOMS, EVALUATION |
| Geographic Terms: |
SWITZERLAND |
| Abstract: |
Background Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. Methods We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status. Results Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P <.001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P <.001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P =.005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1–2 vaccinations (P =.028) and 0.49 with ≥3 prior vaccinations (P =.30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08–3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10–3.46) were significantly associated with the outcome. Conclusions Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
